Answers are grounded in this paper and cite their sources.
Malaria remains a major global health challenge, causing around 600,000 deaths each year. Resistance to current therapies demands new antimalarial agents. Derivative 13 , discovered by high-throughput screening, showed submicromolar potency against both the asexual blood stage (ABS) and gametocyte stage (GCT) of P. falciparum parasite. We optimized the 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (THIP) scaffold through expansion from the imidazole 3-position, systematic substituent screening, and right-hand-side refinement. This improved the potency of hit 13 by up to 80-fold, with compound 73 reaching IC 50 = 8.7 nM against the ABS. Compounds 108 , 110 , and 107 achieved ABS IC 50 values below 50 nM and 100 nM against GCT. Compound 41 was the most active against both stages, with sub-100 nM activity against ABS and GCT. The structure–activity relationship reveals marked structural specificity that governs antiplasmodial activity. These results nominate the THIP scaffold as a promising lead and motivate further optimization toward preclinical development against malaria.
No takes yet. Share an insight, caveat, or question.
Cavina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: